Trade-Ideas LLC identified

Parexel International

(

PRXL

) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Parexel International as such a stock due to the following factors:

  • PRXL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $55.1 million.
  • PRXL is up 4% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PRXL with the Ticky from Trade-Ideas. See the FREE profile for PRXL NOW at Trade-Ideas

More details on PRXL:

PAREXEL International Corp, a biopharmaceutical services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. PRXL has a PE ratio of 26. Currently there are 6 analysts that rate Parexel International a buy, 1 analyst rates it a sell, and 6 rate it a hold.

The average volume for Parexel International has been 583,000 shares per day over the past 30 days. Parexel International has a market cap of $3.4 billion and is part of the health care sector and health services industry. The stock has a beta of 0.56 and a short float of 5.4% with 3.35 days to cover. Shares are down 6.7% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Parexel International as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:

  • PRXL's revenue growth has slightly outpaced the industry average of 5.1%. Since the same quarter one year prior, revenues slightly increased by 2.0%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Life Sciences Tools & Services industry and the overall market, PAREXEL INTERNATIONAL CORP's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
  • Net operating cash flow has significantly increased by 187.01% to $54.20 million when compared to the same quarter last year. In addition, PAREXEL INTERNATIONAL CORP has also vastly surpassed the industry average cash flow growth rate of 7.07%.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • PAREXEL INTERNATIONAL CORP's earnings per share declined by 32.8% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, PAREXEL INTERNATIONAL CORP increased its bottom line by earning $2.66 versus $2.24 in the prior year. This year, the market expects an improvement in earnings ($3.29 versus $2.66).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.